Immunotherapy in psoriasis

被引：9

作者：

Landeck, Lilla ^{[1
]}

Sabat, Robert ^{[2
]}

Ghoreschi, Kamran ^{[3
]}

Man, Xiao-Yong ^{[4
]}

Fuhrmeister, Katja

Gonzalez-Martinez, Ernesto ^{[5
]}

Asadullah, Khusru ^{[3
]}

机构：

[1] Ernst von Bergmann Gen Hosp, Dept Dermatol, D-14467 Potsdam, Germany

[2] Charite Univ Med Berlin, Psoriasis Res & Treatment Ctr, Berlin, Germany

[3] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, Berlin, Germany

[4] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Dermatol & Venereol, Hangzhou, Zhejiang, Peoples R China

[5] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 07期

关键词：

biologicals; COVID-19; cytokines; drug selection; drug targets; immunomodulation; individualized therapy; interleukins; pharmacology; skin inflammation; QUALITY-OF-LIFE; DIFFERENTIAL DRUG SURVIVAL; TUMOR-NECROSIS-FACTOR; OBSERVATIONAL COHORT; BRITISH ASSOCIATION; BIOLOGIC THERAPIES; SKIN; CYTOKINE; IL-22; RISK;

D O I：

10.2217/imt-2020-0292

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Over the past two decades, a huge progress in the treatment of psoriasis was achieved by targeting the human cytokine network. At present, 11 biologicals - antibodies, and a soluble receptor - are used to neutralize key inflammatory cytokines. Based on their targets, they can be grouped into the following four classes: TNF-alpha-, IL-12/23-, IL-17- and IL-23-inhibitors. The number of substances, but also the different modes of action may be challenging, when selecting the right drug for an individual patient. In this article, we provide an overview of the available biologicals in the treatment of psoriasis, including their advantages and limitations, and summarize criteria for therapy selection.

引用

页码：605 / 620

页数：16

共 87 条

[1] Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey [J].

Aggarwal, Bharat B. ;

Gupta, Subash C. ;

Kim, Ji Hye .

BLOOD, 2012, 119 (03) :651-665

[2] Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ [J].

Ainscough, Joseph S. ;

Macleod, Tom ;

McGonagle, Dennis ;

Brakefield, Rosella ;

Baron, Jens M. ;

Alase, Ade ;

Wittmann, Miriam ;

Stacey, Martin .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (13) :E2748-E2757

[3] Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003-2011 [J].

Armstrong, April W. ;

Schupp, Clayton ;

Wu, Julie ;

Bebo, Bruce .

PLOS ONE, 2012, 7 (12)

[4] Novel immunotherapies for psoriasis [J].

Asadullah, K ;

Volk, HD ;

Sterry, W .

TRENDS IN IMMUNOLOGY, 2002, 23 (01) :47-53

[5] IL-10 is a key cytokine in psoriasis -: Proof of principle by IL-10 therapy:: A new therapeutic approach [J].

Asadullah, K ;

Sterry, W ;

Stephanek, K ;

Jasulaitis, D ;

Leupold, M ;

Audring, H ;

Volk, HD ;

Döcke, WD .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :783-794

[6] Industry-academia collaborations for biomarkers [J].

Asadullah, Khusru ;

Busch, Andreas ;

Gottwald, Matthias ;

Reinke, Petra ;

Landeck, Lilla .

NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (12) :805-806

[7]

Belge Katharina, 2014, F1000Prime Rep, V6, P4, DOI 10.12703/P6-4

[8] Psychological well-being in a cohort of women with invasive breast cancer nearly 2 years after diagnosis [J].

Bell, Robin J. ;

Lijovic, Marijana ;

La China, Maria ;

Schwarz, Max ;

Fradkin, Pamela ;

Bradbury, Jo ;

Davis, Susan R. .

SUPPORTIVE CARE IN CANCER, 2010, 18 (08) :921-929

[9] A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions [J].

Bhutani, Tina ;

Patel, Tejas ;

Koo, Bonnie ;

Thao Nguyen ;

Hong, Judith ;

Koo, John .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (02) :e79-e88

[10] Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study [J].

Blauvelt, Andrew ;

Reich, Kristian ;

Tsai, Tsen-Fang ;

Tyring, Stephen ;

Vanaclocha, Francisco ;

Kingo, Kulli ;

Ziv, Michael ;

Pinter, Andreas ;

Vender, Ronald ;

Hugot, Sophie ;

You, Ruquan ;

Milutinovic, Marina ;

Thaci, Diamant .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (01) :60-+

← 1 2 3 4 5 6 7 8 9 →